| Description | SQ-31765 is a blocker of benzazepine calcium channel. |
| In vivo | SQ-31765 (SQ 31,765) can reduce the severity of ischemia in a manner that is independent of changes in myocardial blood flow or hemodynamic alterations. Anesthetized dogs are given saline (n=6), SQ-31765 (n=6; 0.2 mg/kg) or SQ 32,189 (n=6; 0.2 mg/kg) i.v. 10 min before ischemia. The effect on pacing-induced ST-segment elevation (pacing+left anterior descending coronary artery stenosis) and myocardial blood flow are determined. it reduces ST-elevation (P<0.05) compared to saline at 10, 40 and 70 min after infusion (5.9±1.4 and 12.0±1.4 mV, respectively, at 70 min). Left anterior descending coronary artery stenosis during atrial pacing resulted in a significant reduction in subendocardial flow in all groups before drug infusion (41±7, 44±7 and 35±9 mL/min/100 g for saline, SQ-31765 and SQ 32,189, respectively). |
| molecular weight | 464.48 |
| Molecular formula | C24H27F3N2O4 |
| CAS | 138383-07-0 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Grover GJ, et al. Anti-ischemic and vasorelaxant effects of the new benzazepine calcium channel blocker SQ 31,765. J Pharmacol Exp Ther. 1989 Dec;251(3):1020-5. |